Table 4.

Age- and hormone-adjusted odds ratios (OR) and 95% confidence intervals (CI) for the association between adipokines and breast cancer risk, Columbia, MO cohort (67 cases, 67 controls)

Adipokines	Cases		Controls		Age-adjusted OR (95% CI)	p for linear trend2	Estradiol-adjusted OR (95% CI)	p for linear trend2	SHBG-adjusted OR (95% CI)	p for linear trend2
	N	%	N	%
Adiponectin, ng/ml
626–19,535	14	21.5	13	19.4	1.00		1.00		1.00
19,536–25,758	13	20.0	16	23.9	0.55 (0.17, 1.82)		0.65 (0.19–2.25)		0.55 (0.16–1.87)
25,759–32,921	15	23.1	13	19.4	1.50 (0.43, 5.22)		2.11 (0.54–8.20)		1.49 (0.42–5.62)
32,922–73,588	23	35.4	25	37.3	1.16 (0.41, 3.27)	0.90	1.32 (0.45–3.83)	0.34	1.15 (0.39–3.45)	0.39
aPAI-1, pg/ml
1,280–8,048	20	30.3	18	26.9	1.00		1.00		1.00
8,049–12,236	20	30.3	17	25.4	1.01 (0.38, 2.72)		1.10 (0.35–3.49)		1.27 (0.44–3.71)
12,237–17,108	13	19.7	13	19.4	0.82 (0.27, 2.45)		0.67 (0.22–2.11)		0.99 (0.35–2.81)
17,109–57,786	13	19.7	19	28.4	0.49 (0.16, 1.52)	0.25	0.33 (0.10–1.09)	0.06	0.53 (0.19–1.50)	0.23
Resistin, pg/ml
1,280–4,683	20	30.3	18	26.9	1.00		1.00		1.00
4,684–7,551	15	22.7	20	29.9	0.61 (0.23, 1.63)		0.36 (0.12–1.12)		0.43 (0.15–1.25)
7,552–10,653	16	24.2	14	20.9	0.81 (0.27, 2.38)		0.87 (0.24–3.18)		0.83 (0.24–2.87)
10,654–31,407	15	22.7	15	22.4	0.77 (0.28, 2.16)	0.93	0.81 (0.25–2.62)	0.97	0.80 (0.25–2.51)	0.93

¹p-value for linear trend was estimated using the categorical values as an ordinal variable in statistical models